Patient compliance is a critical factor in the effectiveness of cardiac prevention.
Black
Donald M
DM
Global Strategic Regulatory Development, Merck and Company, 126 Lincoln Avenue, Rahway NJ, 07065-0900, USA. donald_black@merck.com
D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000517:prevention & control*; D010349:Patient Compliance; D010359:Patient Readmission; D055502:Secondary Prevention
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors